Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07607938 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Psilocybin as a Novel Therapy for Residual Anhedonia

Name: Psilocybin as a Novel Therapy for Residual Anhedonia — clinical trial record (NCT07607938)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorNYU Langone Health

Started2026-09

View on ClinicalTrials.gov ↗

Amendment history

2026-08-18

Study Status, Study Description, Contacts/Locations v1

Recruitment opened

Start date2026-07→2026-09

2026-05-19

Original filing

NYU Langone Health

394 trials monitored

See 18 trials at risk

This study is for adults with major depressive disorder (depression) who are currently taking an SSRI or SNRI antidepressant but continue to experience anhedonia (reduced interest or pleasure) and emotional blunting. The study will test whether a single 25 mg dose of psilocybin, compared with placebo, can improve these symptoms and improve the function of brain circuits involved in reward and motivation. Researchers will measure changes using brain imaging (fMRI) and clinical questionnaires, including the Dimensional Anhedonia Rating Scale (DARS).

Trial Details

NCT Number	NCT07607938
Lead Sponsor	NYU Langone Health Collaborators: National Institute of Mental Health (NIMH)
Conditions	Anhedonia, Emotional Blunting
Enrollment	90 participants
Start Date	2026-09
Primary Completion	2030-08-01 (estimated)
Study Completion	2030-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-09-15